Tag: XS0432810116

Novartis completes acquisition of Regulus Therapeutics

Basel, June 25, 2025 – Novartis today announced that it has successfully completed its acquisition of Regulus Therapeutics Inc. (“Regulus”). With the completion of the acquisition, shares of common stock, par value $0.001 per share (the “Shares”), of Regulus, have ceased trading on the Nasdaq Stock Market LLC and Regulus is now an indirect wholly owned subsidiary of Novartis.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsXS0432810116

Decision Notice – CIRO Hearing Panel issues its Reasons for Decision in the matter of Scott Nicolas Zurevinski

BAYOTECH SHIFTS NORTHERN CALIFORNIA HYDROGEN HUB DEVELOPMENT TO NEW SITE TO ACCELERATE IMPACT

The Wait is Over: Hard Rock Hotel & Casino Ottawa Opens with Legendary Guitar Smash and Star-Studded Celebration

Tag: XS0432810116

Novartis completes acquisition of Regulus Therapeutics

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us